Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

TEAM: Trial of Early Activity and Mobilization (TEAM)

TEAM: An Multi-centre Observational Study of Early Activity and Mobilization in Australia and New Zealand

Patients in the Intensive Care Unit (ICU) traditionally receive bed rest as part of their care. They develop muscle weakness even after only a few days of mechanical ventilation that may prolong their time in ICU and in hospital, but the nature of such weakness is poorly understood.

The weakness that develops in ICU is more substantial than that which would result from bed rest alone and is referred to as ICU acquired weakness (ICUAW). This weakness might be due to the combination of inflammation and immobility. The exact mechanisms leading to the nerve and muscle damage which occurs in critical illness are not yet fully understood and require further investigation. However, it is known that ICUAW has an effect on a patient's ability to breathe without a ventilator, walk and perform simple activities (like washing and toileting) and often results in longer mechanical ventilation time and hence, longer hospital stays than might otherwise be expected. It may also affect a patient's ability to return home after their hospital stay. The recovery period in Australian and New Zealand ICU patients is unknown but a trial from Canada has reported ongoing weakness five years after leaving ICU. Weakness in survivors of intensive care is known to be a substantial problem. It is currently not known whether ICUAW may be avoided or its severity reduced with simple strategies of early exercise in ICU.

There are no data about the level of activity and mobility in critically ill patients in Australian and New Zealand ICUs. These data are urgently required to plan a program of research to test whether increasing the level of mobility and activity in our critically ill patients is safe, feasible and efficacious in terms of reducing the severity of ICUAW and improving patient-centred outcomes. The program of research will first include a study to observe the mobility levels in 25 ICUs across Australia and New Zealand to determine safety, barriers to mobility and what type of activities are undertaken by our patients.

From the observational data we plan to develop a pilot randomised controlled trial of early mobility and activity in intensive care units across Australia and New Zealand. This simple, cost-effective strategy may improve functional ability, decrease time on mechanical ventilation and improve long term outcomes in this patient group. By initiating such a program, ANZ investigators might be able to change future patient outcomes worldwide.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Real)

192

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Victoria
      • Melbourne, Victoria, Austrália, 3104
        • The Alfred
      • Wellington, Nova Zelândia
        • Wellington Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Intensive care unit patients

Descrição

Inclusion Criteria:

  • they have received invasive mechanical ventilation for at least 24 hours, and have been in ICU less than 72 hours
  • the treating clinician expects the patient to still be receiving invasive mechanical ventilation in the ICU the day after tomorrow.

Exclusion Criteria:

  • Age less than 18 years old

    • Patient has a proven or suspected acute primary brain process that is likely to result in global impairment of conscious level or cognition, such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury after cardiac arrest or asphyxiation.
    • Second or subsequent admission to ICU during a single hospital admission
    • Patient does not speak English
    • Patient has proven or suspected primary myopathic or neurological process associated with prolonged weakness, such as Guillain-Barre syndrome
    • Death is deemed imminent and inevitable
    • Inability to walk without assistance prior to the acute illness that is associated with admission to ICU (use of a cane or walker not an exclusion)
    • Cognitive impairment prior to the acute illness that is associated with admission to ICU (refer data dictionary)
    • Any written "Rest In Bed" or non-weight bearing medical order such as may occur with hip fracture, unstable spine or pelvis, pathological fracture

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: Coorte
  • Perspectivas de Tempo: Prospectivo

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Best level of activity in ICU
Prazo: ICU stay (average 7 days)

Highest level of activity (11 point scale) including:

unknown nothing (lying in bed, passive stretches) sitting in bed, active exercises in bed moved to chair (via hoist, slide etc but no standing) sitting over edge of bed standing transferring bed to chair marching on spot (at bedside) walking with assistance of 2 or more people walking with assistance of 1 person walking independently with a gait aid walking independently without a gait aid

ICU stay (average 7 days)
Dosage of the best level of activity
Prazo: Intensive care unit stay (average 7 days)
The time spent performing the best level of activity and the number of times it is achieved
Intensive care unit stay (average 7 days)
Time to standing in ICU
Prazo: Intensive care stay (average 7 days)
The number of days in ICU before a patient can stand
Intensive care stay (average 7 days)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Best level of activity at hospital discharge
Prazo: Hospital stay (median days 14)

Highest level of activity (11 point scale) including:

unknown nothing (lying in bed, passive stretches) sitting in bed, active exercises in bed passively moved to chair (pat slide, hoist but no standing) sitting over edge of bed standing transferring bed to chair marching on spot (at bedside) walking with assistance of 2 or more people walking with assistance of 1 person walking independently with a gait aid walking independently without a gait aid

Hospital stay (median days 14)
Time to first sit out of bed
Prazo: ICU stay (average 7 days)
The number of days until the patient can sit out of bed
ICU stay (average 7 days)
Barriers to mobilisation
Prazo: Intensive care unit stay (average 7 days)
Factors that may have been a barrier to mobilizing patients in the ICU
Intensive care unit stay (average 7 days)
Mobilization related adverse events
Prazo: Intensive care unit stay (average 7 days)
Adverse events that occured during patient mobilization such as an unplanned extubation or a fall to the floor
Intensive care unit stay (average 7 days)
Time to first physiotherapy
Prazo: Intensive care unit stay (average 7 days)
The number of days in intensive care before the patient was reviewed by a physiotherapist
Intensive care unit stay (average 7 days)
Mechanical ventilation free days
Prazo: 28 days
The number of mechanical ventilation free days to day 28
28 days
Intensive care unit free days
Prazo: Day 28
The number of days the patient spent out of ICU to day 28 (if dead = 0)
Day 28
90 day mortality
Prazo: 90 days
The mortality at day 90
90 days
Health related quality of life at 6 months
Prazo: 6 months
Health related quality of life reported via telephone interview at 6 months using the EuroQoL EQ5D
6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Carol Hodgson, PhD, ANZIC-RC
  • Diretor de estudo: Steve Webb, MD, ANZICS CTG
  • Diretor de estudo: Rinaldo Bellomo, MD, ANZIC-RC
  • Investigador principal: Megan Harrold, PhD Candidate, Royal Perth Hospital
  • Investigador principal: Heidi Buhr, RN, Royal Prince Alfred Hospital, Sydney, Australia
  • Investigador principal: Manoj Saxena, MD, St George Hospital
  • Investigador principal: Paul Young, MD, Wellington Hospital
  • Investigador principal: Oystein Tronstad, PT, Prince Charles Hospital
  • Investigador principal: Neil Orford, MD, Barwon Health

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de julho de 2012

Conclusão Primária (Real)

1 de março de 2014

Conclusão do estudo (Real)

1 de março de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

14 de agosto de 2012

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de agosto de 2012

Primeira postagem (Estimativa)

29 de agosto de 2012

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

6 de maio de 2015

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de maio de 2015

Última verificação

1 de maio de 2015

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • ICF

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever